Showing 1-4 of 4 "Kidney Transplant"

Status: Enrolling

Investigator: Richard Knight

Study Coordinator: Joy Nolte

Phone: 713.441.6314

The purpose of this study is to evaluate the efficacy of ASP0113 compared to placebo in reducing the incidence of cytomegalovirus (CMV) viremia in CMV-seronegative subjects receiving a kidney from a CMV-seropositive donor. This study will also e ... Read more >

Status: Enrolling

Investigator: Richard Knight

Study Coordinator: Alejandro De La Torre

Phone: 000.000.0000

The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-36 months after kidney transplant. ... Read more >

Status: Enrolling

Investigator: Ahmed Gaber

Study Coordinator: Alejandro De La Torre

Phone: 000.000.0000

The purpose of this treatment registry study is to determine if monthly infusions of Intravenous Immunoglobulin (IVIg) for 6 months will neutralize donor specific antibodies that are thought to be responsible for chronic rejection episodes in re ... Read more >

Status: Enrolling

Investigator: Richard Knight

Study Coordinator: Joy Nolte

Phone: 713.441.6314

This is a 2-year, randomized, multicenter, open-label, 2-arm study evaluating the graft function of everolimus and reduced CNI versus MPA and standard CNI in adult de novo renal transplant recipients. ... Read more >